ABOUT US
PRODUCT
PIPELINE
INVESTOR RELATIONS
NEWS
CAREERS
Actimmune® is indicated for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis
Our development programs are focused in the areas of pulmonology and hepatology.
View Development Pipeline
ITMN: NSDQ
Price:
15.50
Change:
-0.20
(
-1.27%
)
Date:
02/08/2010
Time:
00:00 EST
February 1, 2010
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
January 20, 2010
InterMune Announces Pricing of $98.7 Million Public Offering of Common Stock
View All Press Releases
January 13, 2010
Replay of Webcast - InterMune Inc. at JPMorgan Healthcare Conference
View Our Event Calendar
© InterMune 2004 |
Terms and Conditions
| Privacy Policy
CONTACT US
SITE MAP
SEARCH
built@zoomedia
Corporate Overview
Executive Management Team
Board of Directors
Corporate Compliance
Corporate Governance
ActimmuneŽ
Development Pipeline
Preclinical and Applied Research
Analyst Coverage
Annual Reports
E-mail Alerts
Event Calendar
Information Request
Insider Trading
SEC Filings
Stock Information
News Release Archive
Benefits
Opportunities